{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:36:36Z","timestamp":1792272996408,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3300905"],"award-info":[{"award-number":["2022YFC3300905"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00213-024-06703-9","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T03:36:14Z","timestamp":1728963374000},"page":"533-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of pharmacological effects and abuse potential of 5F-EDMB-PICA, CUMYL-PEGACLONE, and NM-2201 in mice"],"prefix":"10.1007","volume":"242","author":[{"given":"Kaixi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"6703_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s002130000569","volume":"153","author":"MT Bardo","year":"2000","unstructured":"Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153:31\u201343. https:\/\/doi.org\/10.1007\/s002130000569","journal-title":"Psychopharmacology"},{"key":"6703_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1089\/can.2019.0003","volume":"5","author":"CS Breivogel","year":"2020","unstructured":"Breivogel CS, Wells JR, Jonas A et al (2020) Comparison of the neurotoxic and seizure-inducing effects of Synthetic and endogenous cannabinoids with \u2206 9 -Tetrahydrocannabinol. Cannabis Cannabinoid Res 5:32\u201341. https:\/\/doi.org\/10.1089\/can.2019.0003","journal-title":"Cannabis Cannabinoid Res"},{"key":"6703_CR3","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1007\/s00213-016-4402-y","volume":"233","author":"I Canazza","year":"2016","unstructured":"Canazza I, Ossato A, Trapella C et al (2016) Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on tetrad, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology 233:3685\u20133709. https:\/\/doi.org\/10.1007\/s00213-016-4402-y","journal-title":"Psychopharmacology"},{"key":"6703_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11419-016-0326-9","volume":"35","author":"X Diao","year":"2017","unstructured":"Diao X, Carlier J, Zhu M et al (2017) In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol 35:20\u201332. https:\/\/doi.org\/10.1007\/s11419-016-0326-9","journal-title":"Forensic Toxicol"},{"key":"6703_CR5","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/npp.2010.44","volume":"35","author":"KW Falenski","year":"2010","unstructured":"Falenski KW, Thorpe AJ, Schlosburg JE et al (2010) FAAH\u2013\/\u2013 mice Display Differential Tolerance, Dependence, and cannabinoid receptor adaptation after \u22069-Tetrahydrocannabinol and Anandamide Administration. Neuropsychopharmacology 35:1775\u20131787. https:\/\/doi.org\/10.1038\/npp.2010.44","journal-title":"Neuropsychopharmacology"},{"key":"6703_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pbb.2016.01.007","volume":"152","author":"JS Fogel","year":"2017","unstructured":"Fogel JS, Kelly TH, Westgate PM, Lile JA (2017) Sex differences in the subjective effects of oral \u22069-THC in cannabis users. Pharmacol Biochem Behav 152:44\u201351. https:\/\/doi.org\/10.1016\/j.pbb.2016.01.007","journal-title":"Pharmacol Biochem Behav"},{"key":"6703_CR7","doi-asserted-by":"publisher","unstructured":"Foll BL, Wiggins M, Goldberg SR (2006) Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of D-9-tetrahydrocannabinol in rats. https:\/\/doi.org\/10.1097\/01.fbp.0000197460.16516.81","DOI":"10.1097\/01.fbp.0000197460.16516.81"},{"key":"6703_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00213-017-4783-6","volume":"235","author":"MB Gatch","year":"2018","unstructured":"Gatch MB, Forster MJ (2018) \u22069-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. Psychopharmacology 235:673\u2013680. https:\/\/doi.org\/10.1007\/s00213-017-4783-6","journal-title":"Psychopharmacology"},{"key":"6703_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/dta.3405","volume":"15","author":"A Giorgetti","year":"2023","unstructured":"Giorgetti A, Brunetti P, Haschimi B et al (2023) Human phase-I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F\u2010EDMB\u2010PICA and EDMB\u2010PINACA. Drug Test Anal 15:299\u2013313. https:\/\/doi.org\/10.1002\/dta.3405","journal-title":"Drug Test Anal"},{"key":"6703_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/dta.2545","volume":"11","author":"S Halter","year":"2019","unstructured":"Halter S, Angerer V, R\u00f6hrich J et al (2019) Cumyl-PEGACLONE: a comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Drug Test Anal 11:347\u2013349. https:\/\/doi.org\/10.1002\/dta.2545","journal-title":"Drug Test Anal"},{"key":"6703_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11419-016-0320-2","volume":"34","author":"C Hess","year":"2016","unstructured":"Hess C, Schoeder CT, Pillaiyar T et al (2016) Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol 34:329\u2013343. https:\/\/doi.org\/10.1007\/s11419-016-0320-2","journal-title":"Forensic Toxicol"},{"key":"6703_CR12","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.neuropharm.2011.12.028","volume":"62","author":"A Higuera-Matas","year":"2012","unstructured":"Higuera-Matas A, Migu\u00e9ns M, Coria SM et al (2012) Sex-specific disturbances of the glutamate\/GABA balance in the hippocampus of adult rats subjected to adolescent cannabinoid exposure. Neuropharmacology 62:1975\u20131984. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.12.028","journal-title":"Neuropharmacology"},{"key":"6703_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"AC Howlett","year":"2002","unstructured":"Howlett AC (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161\u2013202. https:\/\/doi.org\/10.1124\/pr.54.2.161","journal-title":"Pharmacol Rev"},{"key":"6703_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/7854_2016_16","volume-title":"Neuropharmacology of New Psychoactive substances (NPS)","author":"TUC J\u00e4rbe","year":"2016","unstructured":"J\u00e4rbe TUC, Raghav JG (2016) Tripping with synthetic cannabinoids (spice): anecdotal and experimental observations in animals and man. In: Baumann MH, Glennon RA, Wiley JL (eds) Neuropharmacology of New Psychoactive substances (NPS). Springer International Publishing, Cham, pp 263\u2013281"},{"key":"6703_CR15","doi-asserted-by":"publisher","unstructured":"Lichtman AH, Fisher J, Martin BR (2001) Precipitated cannabinoid withdrawal is reversed by D9-tetrahydrocannabinol or clonidine. https:\/\/doi.org\/10.1016\/s0091-3057(01)00514-7","DOI":"10.1016\/s0091-3057(01)00514-7"},{"key":"6703_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nchembio.129","volume":"5","author":"JZ Long","year":"2009","unstructured":"Long JZ, Li W, Booker L et al (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37\u201344. https:\/\/doi.org\/10.1038\/nchembio.129","journal-title":"Nat Chem Biol"},{"key":"6703_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","volume":"94","author":"D Luethi","year":"2020","unstructured":"Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects. Arch Toxicol 94:1085\u20131133. https:\/\/doi.org\/10.1007\/s00204-020-02693-7","journal-title":"Arch Toxicol"},{"key":"6703_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/sj.bjp.0705931","volume":"143","author":"CR Lupica","year":"2004","unstructured":"Lupica CR, Riegel AC, Hoffman AF (2004) Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 143:227\u2013234. https:\/\/doi.org\/10.1038\/sj.bjp.0705931","journal-title":"Br J Pharmacol"},{"key":"6703_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/dta.2352","volume":"10","author":"L Mogler","year":"2018","unstructured":"Mogler L, Wilde M, Huppertz LM et al (2018) Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples. Drug Test Anal 10:886\u2013891. https:\/\/doi.org\/10.1002\/dta.2352","journal-title":"Drug Test Anal"},{"key":"6703_CR20","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/dta.2685","volume":"11","author":"C Nash","year":"2019","unstructured":"Nash C, Glowacki L, Gerostamoulos D et al (2019) Identification of a thermal degradation product of CUMYL-PEGACLONE and its detection in biological samples. Drug Test Anal 11:1480\u20131485. https:\/\/doi.org\/10.1002\/dta.2685","journal-title":"Drug Test Anal"},{"key":"6703_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuropharm.2016.05.021","volume":"109","author":"JD Nguyen","year":"2016","unstructured":"Nguyen JD, Aarde SM, Vandewater SA et al (2016) Inhaled delivery of \u22069-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology. Neuropharmacology 109:112\u2013120. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.05.021","journal-title":"Neuropharmacology"},{"key":"6703_CR22","doi-asserted-by":"publisher","first-page":"e12940","DOI":"10.1111\/adb.12940","volume":"26","author":"JF Oliveira Da Cruz","year":"2021","unstructured":"Oliveira Da Cruz JF, Ioannidou C, Pagano Zottola AC et al (2021) Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB\u2010Fubinaca. Addict Biol 26:e12940. https:\/\/doi.org\/10.1111\/adb.12940","journal-title":"Addict Biol"},{"key":"6703_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.116.238717","volume":"361","author":"BF Thomas","year":"2017","unstructured":"Thomas BF, Lefever TW, Cortes RA et al (2017) Thermolytic degradation of Synthetic cannabinoids: Chemical exposures and Pharmacological consequences. J Pharmacol Exp Ther 361:162\u2013171. https:\/\/doi.org\/10.1124\/jpet.116.238717","journal-title":"J Pharmacol Exp Ther"},{"key":"6703_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.05.029","volume":"191","author":"KR Trexler","year":"2018","unstructured":"Trexler KR, Nass SR, Crowe MS et al (2018) Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice. Drug Alcohol Depend 191:14\u201324. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.05.029","journal-title":"Drug Alcohol Depend"},{"key":"6703_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0014-2999(01)01267-5","volume":"430","author":"AH Tseng","year":"2001","unstructured":"Tseng AH, Craft RM (2001) Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol 430:41\u201347. https:\/\/doi.org\/10.1016\/S0014-2999(01)01267-5","journal-title":"Eur J Pharmacol"},{"key":"6703_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/jpet.104.080739","volume":"314","author":"SA Varvel","year":"2005","unstructured":"Varvel SA, Bridgen DT, Tao Q et al (2005) \u2206 9 -Tetrahydrocannbinol accounts for the Antinociceptive, hypothermic, and Cataleptic effects of Marijuana in mice. J Pharmacol Exp Ther 314:329\u2013337. https:\/\/doi.org\/10.1124\/jpet.104.080739","journal-title":"J Pharmacol Exp Ther"},{"key":"6703_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.11.035","volume":"172","author":"JL Wiley","year":"2017","unstructured":"Wiley JL, Lefever TW, Marusich JA, Craft RM (2017) Comparison of the discriminative stimulus and response rate effects of \u22069-tetrahydrocannabinol and synthetic cannabinoids in female and male rats. Drug Alcohol Depend 172:51\u201359. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.11.035","journal-title":"Drug Alcohol Depend"},{"key":"6703_CR28","doi-asserted-by":"publisher","first-page":"109468","DOI":"10.1016\/j.drugalcdep.2022.109468","volume":"236","author":"CD Wilson","year":"2022","unstructured":"Wilson CD, Hiranita T, Fantegrossi WE (2022) Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. Drug Alcohol Depend 236:109468. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109468","journal-title":"Drug Alcohol Depend"},{"key":"6703_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1021\/acsptsci.9b00069","volume":"3","author":"E Wouters","year":"2020","unstructured":"Wouters E, Walraed J, Robertson MJ et al (2020) Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacol Transl Sci 3:285\u2013295. https:\/\/doi.org\/10.1021\/acsptsci.9b00069","journal-title":"ACS Pharmacol Transl Sci"},{"key":"6703_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11419-021-00605-7","volume":"40","author":"F Xu","year":"2022","unstructured":"Xu F, Wei W, Shan X et al (2022) Identification and characterization of novel synthetic cannabinoid ethyl-2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PICA). Forensic Toxicol 40:163\u2013172. https:\/\/doi.org\/10.1007\/s11419-021-00605-7","journal-title":"Forensic Toxicol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06703-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T03:09:42Z","timestamp":1740539382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06703-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6703"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06703-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}